HIV Vaccines

Country: Canada

City: Alberta

Abstr. due: 17.10.2014

Dates: 22.03.15 — 27.03.15

Area Of Sciences: Biology;

Organizing comittee e-mail:

Organizers: Keystone Symposia



As the 30th anniversary of the discovery of HIV has come and gone, HIV remains a catastrophic public health concern, with an estimated global prevalence of 34 million HIV-infected persons. Despite the remarkable advances in the development of several biomedical interventions for the prevention of HIV, the importance of developing an effective HIV vaccine has been recognized by a wide spectrum of the scientific community and civil society. Important milestones for the HIV vaccine field were the demonstration that a vaccine regimen could reduce HIV acquisition and the identification of binding IgG envelope (env) antibodies as potential correlates of protection from HIV acquisition. However, broad neutralizing antibodies (bNAbs) are thought to be the main mechanism of protection of the currently available effective vaccines. The present meeting will address the major scientific gaps in the the generation of env bNAbs. The major goals of the meeting include: 1) To understand the development of bNAbs in natural infections and following vaccination; 2) To determine predictors of response to vaccines; 3) To review the advances in envelope immunogen design; 4) The therapeutic use of bNAbs; 5) The application of novel technologies to monitor the immune response; and 6) The development of therapeutic strategies aimed to functional HIV cure. The meeting will bring together interdisciplinary groups with outstanding expertise in B- and T-cell biology, structural biology, vaccinology and clinical science. It will therefore provide to the attendees how innovative basic observations from the bench side may translate into the clinical development of vaccines and therapeutic interventions.

Conference Web-Site: